Actio Biosciences – ABS-0871

The Phase I study is a randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and pharmacokinetics of ABS-0871 in healthy volunteers. Pharmacokinetics refers to how a drug is absorbed, distributed, broken down, and eliminated from the body. Data from this study will inform future clinical trials in CMT2C.